Effect of Esketamine on Depressive Symptoms of Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy (EDSOP)
This interventional trial (n=400) investigates the effect of esketamine infusion during laparoscopic sleeve gastrectomy on postoperative depressive symptoms among obese patients.
Details
Randomised, double-blind, parallel-group trial comparing a standardized non-opioid anaesthesia strategy using intraoperative esketamine infusion versus standard opioid-based general anaesthesia in obese patients undergoing laparoscopic sleeve gastrectomy.
Primary objective is to evaluate postoperative depressive symptoms (HAMD) after esketamine-based anaesthesia; secondary outcomes include perioperative analgesia, opioid-related complications, and safety/tolerability.
Intervention arm receives loading esketamine 0.25 mg/kg with continuous intraoperative infusion (~0.25 mg/kg/h) plus dexmedetomidine; control arm receives induction sufentanil and remifentanil infusion with standard maintenance agents.